Qu Biologics Granted Broad New Zealand Patent Involving Immunotherapies Derived from Viruses for Treating a Range of Cancers

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 4, 2014) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's immune system, announced it has been granted its second broad New Zealand patent.

Qu Biologics has been issued New Zealand Patent No.601232. The granted patent involves using components of viruses to stimulate an immune response to treat a range of cancers.

Dr. Hal Gunn, Chief Executive Officer of Qu Biologics commented, "This important patent broadens our patent scope to include the use of inactivated viral components for the treatment of cancer." Dr. Gunn added, "SSIs, derived from inactivated bacterial and viral components, activate an innate immune response in the specific organ or tissue commonly infected by the pathogen. Since innate immune system defect or deficiency plays an important underlying role in cancer or other immune-related diseases, this site-directed immunostimulation represents a promising new approach to engaging the body's own immune response for the treatment of these important diseases."

Qu Biologics develops immunotherapies called Site Specific Immunomodulators (SSIs), which are derived from inactivated bacteria or viruses aimed at stimulating the body's immune system against cancer and immune-related disease. The company's SSI platform represents a promising new approach to the treatment of cancer and immune-related disease by addressing the underlying immunological factors. Qu Biologics has developed multiple SSIs, each of which targets a specific tissue/organ system.

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related disease. The company is currently recruiting participants for a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn's disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.